Molecular Signatures of Early-Onset Neonatal Sepsis in Umbilical Cord Blood

脐带血中早发性新生儿败血症的分子特征

• 批准号: 10330562
• 负责人: Leena Bhattacharya Mithal
• 金额: $ 18.99万
• 依托单位: LURIE CHILDREN'S HOSPITAL OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-04 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10330562
• 关键词: Acute-Phase Proteins; Address; Advisory Committees; Affect; Antibiotic Therapy; Antibiotics; Archives; Area; Bacteremia; Bacterial Antibiotic Resistance; Bacterial Infections; Bioinformatics; Biological Markers; Biometry; Birth; Blood Proteins; C-reactive protein; Cessation of life; Clinical; Collaborations; Data; Decision Analysis; Decision Making; Decision Modeling; Development; Diagnosis; Diagnostic; Diagnostic Factor; Diagnostic Procedure; Diagnostic tests; Doctor of Philosophy; Early identification; Enrollment; Enzyme-Linked Immunosorbent Assay; Exposure to; Fetal Development; Foundations; Functional disorder; Future; Gestational Age; Glean; Goals; Haptoglobins; Immune; Immune response; Immunoassay; Immunologics; Immunology; In Vitro; Individual; Infant; Infant Care; Infant Health; Infant Mortality; Infection; Infection Control; Inflammation; Inflammatory; Investigation; Knowledge; Laboratories; Laboratory Markers; Lead; Life; Longitudinal cohort; Machine Learning; Mass Spectrum Analysis; Measures; Mentorship; Methods; Modeling; Molecular Profiling; Morbidity - disease rate; Multicenter Trials; Mycoses; Necrotizing Enterocolitis; Newborn Infant; Outcome; Pathway Analysis; Pathway interactions; Perinatal; Perinatal Infection; Placenta; Predictive Value; Pregnancy; Premature Birth; Premature Infant; Proteins; Proteome; Proteomics; Research; Research Design; Research Personnel; Sampling; Seeds; Sepsis; Serum Proteins; Serum amyloid A protein; Set protein; Side; Site; Technology; Testing; Time; Tissues; Training; Translational Research; Umbilical Cord Blood; Universities; Validation; Variant; Work; accurate diagnosis; adverse outcome; antibiotic resistant infections; biomarker discovery; candidate marker; career; career development; case control; clinical care; clinical practice; clinically actionable; cohort; comparative; design; diagnostic algorithm; diagnostic biomarker; diagnostic strategy; diagnostic tool; differential expression; early onset; evidence base; experience; fetal; hearing impairment; high risk; improved; infant morbidity; innovation; insight; intrauterine environment; microbiome alteration; neonatal infection; neonatal outcome; neonatal sepsis; novel; novel diagnostics; pathogenic bacteria; postnatal; premature; programs; prospective; protein biomarkers; protein expression; research and development; research study; risk prediction; risk stratification; sex; skills; targeted treatment; tool; translational research program

PROJECT SUMMARY Early-onset sepsis (EOS) due to invasive bacterial infection is a leading cause of morbidity in infants and disproportionately affects those born preterm. Accurate diagnosis of EOS remains inadequate. The low sensitivity and delayed time to culture results combined with the poor predictive values of available laboratory markers leads to our inability to rule-out EOS. Thus, infants are exposed to extended duration broad-spectrum empiric antibiotics, which have serious associated adverse consequences such as necrotizing enterocolitis, antibiotic resistant infections, and an altered microbiome. The proposed research will apply proteomics to identify gestational age-specific umbilical cord blood markers toward development of a proposed diagnostic tool with strong negative risk prediction for EOS. Cord blood is promising to identify EOS as it reflects the intrauterine environment where infection originates in preterm birth. In previous work, we found that inflammatory proteins serum amyloid A, C-reactive protein and haptoglobin are substantially elevated in cord blood of preterm infants with culture-confirmed EOS. These data inform our hypothesis that a combination of cord blood proteins provides a signature to differentiate impending EOS and uninfected states. Archived cord blood from infants in an existing longitudinal cohort will be used in a nested case-control design. Aim 1 will measure the cord blood proteome of uninfected infants (controls) across gestational ages using an untargeted proteomics approach to characterize the developmental spectrum. Aim 2(a) will then determine the cord blood proteome signatures of infants with confirmed EOS (cEOS) and culture-negative presumed sepsis (PS). cEOS will be compared to matched controls to identify differentially expressed proteins and candidate markers. PS proteomes will be analyzed to help delineate true infection versus inflammatory subtypes in this heterogeneous group. Bioinformatics pathway analysis may provide novel insights into fetal immune response. Aim 2(b) will determine the best combination of markers to exclude EOS through machine learning decision analysis of proteomics data. Paired placental proteomics in Aim 2(c) will explore origins of fetal inflammation. Aim 3(a) will quantify candidate proteins by an orthogonal immunoassay method. In a validation set of new subjects, Aim 3(b) will measure candidate markers by targeted proteomics and test application of the proposed diagnostic tool. With formal didactics and a mentorship team at Northwestern University with expertise in prematurity, sepsis, biomarker discovery, biostatistics, and decision modeling led by Patrick Seed MD Ph.D., the candidate will gain advanced translational research experience and skills in perinatal research study design, advanced immunology, proteomics, and bioinformatics to further her research agenda. The proposed research and career development will be fundamental towards achieving the candidate’s career goals to: 1) lead a clinical-translational research program on the pathophysiology and host responses of perinatal infection and 2) bring new, reliable sepsis diagnostics to clinical practice, to improve neonatal outcomes through targeted treatment of EOS and antibiotic stewardship.

项目总结